Clinical Trials Browser

Interventional × Somatostatinoma × Octreotide × Clear all

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT01204476 2016-07-15

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Phase 1 Completed

27 enrolled

CNSDermatologicEndocrine

Glucagonoma, Insulinoma, Paraganglioma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary

NCT00227773 2015-10-08

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Phase 2 Withdrawn

Endocrine

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00466856 2012-05-18

Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors

Phase 2 Terminated

10 enrolled

EndocrineHead & Neck

Vipoma, Glucagonoma, Head and Neck Neoplasms, Insulinoma, Adenoma, Islet Cell, Neoplasm Metastasis, Neoplasms, Pheochromocytoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Carcinoma, Medullary

Clinical Trials

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors